Clinical trials: Hematopoietic Malignancy
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Tocilizumab for Patients With Cancer and COVID-19 Disease
This phase II expanded access trial will study how well tocilizumab works in reducing the serious symptoms including pneumonitis (severe acute respiratory distress) in patients with cancer and COVID-19.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis
- Trial name
- NCT04370834
- Testing
- Tocilizumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor bone marrow or stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00255710
- Testing
- filgrastim, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
B-Cell Lymphoid Malignancies, Hematologic Malignancy
Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies
This research study is being conducted to treat patients with B-cell lymphoid malignancies. These types of cancers include diffuse large cell (DLBCL) non-Hodgkin's lymphoma (NHL), mantle cell NHL, any indolent B cell NHL (such as…
- Conditions
- B-Cell Lymphoid Malignancies, Hematologic Malignancy, Non-Hodgkin Lymphoma
- Trial name
- NCT04684979
- Testing
- Hematopoietic Stem Cells from HLA-compatible Related, Hematopoietic Stem Cells from HLA Unrelated
- Where
- United States
- Sponsor
- Baptist Health South Florida
Chemotherapy-Induced Peripheral Neuropathy, Malignant Solid Neoplasm
Evaluating a Mobile Health Application Intervention for Caregiver Instruction in Manual Therapy for Chemotherapy-Induced Peripheral Neuropathy
This clinical trial assesses the impact of a family caregiver-delivered massage technique for use in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN).
- Conditions
- Chemotherapy-Induced Peripheral Neuropathy, Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
- Trial name
- NCT06945380
- Testing
- Best Practice, Comparator Program, Best Practice, Usual Care, Internet-Based Intervention
- Where
- United States
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Hematologic Neoplasms
Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients
Allogeneic (Allo) hematopoietic stem cell transplantation (HSCT) is a recognized curative procedure for hematological malignancies.
- Trial name
- HAPLOMUD (NCT02623309)
- Testing
- Allogeneic (Allo) hematopoietic stem cell transplantation
- Where
- 14 sites in France
- Volunteers
- 108 people
- Sponsor
- Institut Paoli-Calmettes
Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
This pilot phase II trial studies how well high dose cyclophosphamide, tacrolimus, and mycophenolate mofetil work in preventing graft versus host disease in patients with hematological malignancies undergoing myeloablative or…
- Conditions
- Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03128359
- Testing
- Busulfan, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- City of Hope Medical Center
B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cancer
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
RATIONALE: Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and the best dose of carfilzomib in treating patients…
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cancer, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
- Trial name
- NCT01212380
- Testing
- carfilzomib, Cytokine Assessment, Pharmacodynamic Studies
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Relapsed Hematologic Malignancy, Multiple Myeloma
Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant
Multiple Myeloma (MM) is a morbid disease which can only be cured with an allogeneic hematopoietic stem cell transplant (HSCT). Approximately 50% of allotransplanted patients will relapse, with a median survival of 5 years.
- Trial name
- NCT03413800
- Testing
- Lenalidomide-Dexamethasone-DLI
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm
Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study
This phase I trial studies the process by which sotrovimab is absorbed, distributed, metabolized, and eliminated by the body (pharmacokinetics) in hematopoietic stem cell transplant recipients.
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT05135650
- Testing
- Questionnaire Administration, Sotrovimab, Biospecimen Collection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
This is a phase I clinical trial. Patients with a diagnosis of multiple myeloma undergoing autologous transplantation will receive a preparative regimen of melphalan, bendamustine, and carfilzomib.
- Trial name
- NCT02148913
- Testing
- Cohort 1: Carfilzomib 15 mg/m2, Cohort 2: Carfilzomib 20 mg/m2, Cohort 2b: Carfilzomib 20 mg/m2
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Corewell Health West
Graft Versus Host Disease, Leukemia
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00014469
- Testing
- busulfan, melphalan, methotrexate
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Extensive Stage Small Cell Lung Cancer
Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC
The goal of this clinical trial is to learn if hematopoietic stem cell transplantation-supported dose-dense chemotherepy with adebrelimb works to treat extensive-stage small-cell lung cancer in adults.
- Trial name
- NCT06597513
- Testing
- auto-HSCT-Supported Dose-Dense Chemotherapy With Adebrelimab
- Volunteers
- 10 people
- Sponsor
- Zhou Chengzhi
Neutropenic Enterocolitis, Myeloablative Chemotherapy Induced Bone Marrow Aplasia
Effectiveness and Safety of MMSCs for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis
Subjects will undergo peripheral blood stem cell mobilisation and collection with subsequent high-dose chemotherapy. After finalization of high-dose chemotherapy subjects will receive bone marrow derived allogeneic multipotent…
- Trial name
- NCT02145923
- Testing
- Peripheral blood stem cell mobilisation and collection, High-dose chemotherapy, Bone marrow derived allogeneic MMSCs infusion
- Where
- Russia
- Volunteers
- 16 people
- Sponsor
- Burnasyan Federal Medical Biophysical Center
Minimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell Transplantation
HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT
Allogeneic hematopoietic cell transplantation (Allo-HSCT) is an effective therapy for acute leukemia, but relapse is the most common problem affecting long-term survivors of allo-HSCT.
- Trial name
- NCT03662087
- Testing
- HMA+DLI, DLI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hematologic Malignancy
B-Cell Reconstitution After Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for a variety of hematological malignancies.
- Trial name
- B-REC (NCT04682314)
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Myeloma
High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma
High-dose chemotherapy and autologous stem cell transplantation (ASCT) as part of the up-front treatment of patients with multiple myeloma has been associated with improved disease-free and overall survival in multiple large…
- Trial name
- NCT02416206
- Testing
- BeEAM
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Northside Hospital, Inc.
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00134017
- Testing
- Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Malignant Solid Neoplasm, Anorexia
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced).
- Conditions
- Advanced Malignant Solid Neoplasm, Anorexia, Hematopoietic and Lymphoid Cell Neoplasm
- Trial name
- NCT04939090
- Testing
- Olanzapine, Megestrol Acetate, Questionnaire Administration
- Where
- 293 sites in United States
- Volunteers
- 227 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
This phase II trial investigates how well duloxetine and neurofeedback training work in treating patients with chemotherapy induced peripheral neuropathy.
- Conditions
- Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04560673
- Testing
- Duloxetine, Neurofeedback, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 336 people
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Malignancies, Hematologic Disorders
Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients
This study reviews patients who received haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Some patients develop donor-specific antibodies (DSA), which can block engraftment and cause transplant failure.
- Conditions
- Hematologic Malignancies, Hematologic Disorders, Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), Graft Failure
- Trial name
- PAIA-Haplo (NCT07200583)
- Testing
- Protein A immunoadsorption, Rituximab (optional, in some patients), Bortezomib (optional, in some patients)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ting YANG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.